Predicting Dose-Response to Prostate Cancer Radiotherapy: Validation of a Radiation Signature in the Randomized Phase III NRG/RTOG 0126 and SAKK 09/10 Trials

🔗 Access full article via Annals of Oncology

The SAKK 09/10 trial randomized biochemically-recurrent prostate cancer patients to salvage radiation 64Gy vs. 70Gy, and the NRG/RTOG 0126 randomized intermediate-risk prostate cancer patients to definitive radiation 70.2Gy vs. 79.2Gy. We investigated a previously developed Post-Operative Radiation Therapy Outcomes Score (PORTOS) to identify preferential benefit from radiation dose escalation (DE).